
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NN-840
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : National Institutes of Health
Deal Size : $2.5 million
Deal Type : Funding
NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance NN-840
Details : The proceeds will support development of its innovative TNF-alpha inhibitor NN-840 program for Alzheimer’s disease and other neurodegenerative conditions.
Product Name : NN-840
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
September 10, 2025
Lead Product(s) : NN-840
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : National Institutes of Health
Deal Size : $2.5 million
Deal Type : Funding
